Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: A randomized, double-blind, phase III study (HORIZON II)

Journal of Clinical Oncology

Volumn 30, Issue 29, 2012, Pages 3596-3603

  Hoff, Paulo M ^a,b   Hochhaus, Andreas ^d   Pestalozzi, Bernhard C ^e   Tebbutt, Niall C ^f   Li, Jin ^g   Kim, Tae Won ⁱ   Koynov, Krassimir D ^j   Kurteva, Galina ^k   Pintér, Tamás ^l   Cheng, Ying ^h   Van Eyll, Brigitte ^c   Pike, Laura ^m   Fielding, Anitra ^m   Robertson, Jane D ^m   Saunders, Mark P ⁿ  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c Instituto do Cancer Dr Arnaldo   (Brazil)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f AUSTIN HEALTH   (Australia)

^g FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^h Jilin Provincial Tumor Hospital   (China)

ⁱ University of Ulsan   (South Korea)

^j Cardiology Clinic Professor Kiril Chichovski   (Bulgaria)

^k National Oncology Center Bulgaria   (Bulgaria)

^l Petz Aladár Hospital   (Hungary)

^m ASTRAZENECA   (United Kingdom)

ⁿ CHRISTIE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CEDIRANIB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAZIL; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; QUINAZOLINES; SURVIVAL ANALYSIS;

EID: 84867602281     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.6031     Document Type: Article

References (24)

1. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000 (Pubitemid 30644117)
2. Goldberg RM: Current approaches to first-line treatment of advanced colorectal cancer. Clin Colorectal Cancer 4:S9-S15, 2004 (suppl 1)
3. Cassidy J, Clarke S, Díaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006-2012, 2008
4. Ducreux M, Bennouna J, Hebbar M, et al: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 128:682-690, 2011
5. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
6. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389-4400, 2005 (Pubitemid 40775678)
7. Drevs J, Medinger M, Mross K, et al: Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 23:121s, 2005 (suppl; abstr 3002)
8. Lorusso P, Shields AF, Gadgeel S, et al: Cediranib in combination with various anticancer regimens: Results of a phase I multi-cohort study. Invest New Drugs 29:1395-1405, 2011
9. Chen E, Jonker D, Gauthier I, et al: Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer. Clin Cancer Res 15:1481-1486, 2009
10. Schmoll H, Cunningham D, Sobrero A, et al: mFOLFOX6 + cediranib vs mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): A randomized, double-blind, Phase II/III study (HORIZON III). Ann Oncol 21:viii188, 2010 (suppl 8; abstr 580O)
11. Schmoll H-J, Cunningham D, Sobrero A, et al: Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30:3588-3595, 2012
12. Köhne CH, Cunningham D, Di Costanzo F, et al: Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 13:308-317, 2002 (Pubitemid 34704985)
13. Maindrault-Goebel F, Lledo G, Chibaudel B, et al: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol 25:166s, 2007 (suppl; abstr 4013)
14. Saltz L, Clarke S, Diaz-Rubio E, et al: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 25:170s, 2007 (suppl; abstr 4028)
15. AstraZeneca:GlobalPolicy:Bioethics.2011.http://www.astrazeneca.com/ Responsibility/Code-policies-standards
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Whitehead J: The analysis of relapse clinical trials, with application to a comparison of two ulcer treatments. Stat Med 8:1439-1454, 1989
18. Ellis S, Carroll KJ, Pemberton K: Analysis of duration of response in oncology trials. Contemp Clin Trials 29:456-465, 2008
19. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
20. Hecht JR, Trarbach T, Hainsworth JD, et al: Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997-2003, 2011
21. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2009
22. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
23. Chiappa A, Makuuchi M, Lygidakis NJ, et al: The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. Crit Rev Oncol Hematol 72:65-75, 2009
24. Goodwin R, Ding K, Seymour L, et al: Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 21:2220-2226, 2010